Daniel Farraye

Daniel is an associate in the firm’s Antitrust and Competition practice. He helps businesses across several industries, including Life Sciences, Healthcare, and Technology, navigate complex competition laws, from government antitrust investigations and litigation to regulatory compliance. A core part of his practice involves advising clients on pre-merger strategies and Hart-Scott-Rodino requirements.

Daniel dedicates time to various pro bono services, including representing a class of unaccompanied children seeking to obtain permanent resident status.

Daniel is a member of the DC Bar.

Daniel’s recent representative experience includes:

• Vega Therapeutics, Inc., in its acquisition by Incyte Corporation for $1.25 billion upfront and up to $750 million in milestones, for a total of up to $2 billion
• Perfuse Therapeutics in its acquisition by Bayer for up to $2.45 billion
• Frazier Healthcare Partners in its acquisition of Altruix
• Ouro Medicines in its acquisition by Gilead Sciences for $1.675 billion upfront and up to $500 million in milestones, for a total of up to $2.375 billion
• Orna Therapeutics in its acquisition by Eli Lilly for up to $2.4 billion
• Kingswood Capital Management in its acquisition of Safran Passenger Innovations

Recent representative litigation matters:

• A real estate company in antitrust litigation alleging anticompetitive use of a pricing algorithm software

Daniel contributes to Goodwin’s Antitrust Trends in Technology, Life Sciences, and Healthcare series, which provides analysis and commentary on antitrust developments, and Goodwin’s resource on State Healthcare Transaction Notification (mini-HSR) Laws. Additionally, he writes for Goodwin’s Big Molecule Watch blog.

• Co-Author, “FTC Launches Healthcare Task Force, Signaling Heightened Antitrust and Consumer Protection Enforcement,” Goodwin Client Alert, March 24, 2026